ATE290866T1 - USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF NEURODEGENERATIVE OPHTHALMIC DISEASES - Google Patents

USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF NEURODEGENERATIVE OPHTHALMIC DISEASES

Info

Publication number
ATE290866T1
ATE290866T1 AT99965071T AT99965071T ATE290866T1 AT E290866 T1 ATE290866 T1 AT E290866T1 AT 99965071 T AT99965071 T AT 99965071T AT 99965071 T AT99965071 T AT 99965071T AT E290866 T1 ATE290866 T1 AT E290866T1
Authority
AT
Austria
Prior art keywords
treatment
neurotrophic factor
ophthalmic diseases
factor stimulators
neurodegenerative
Prior art date
Application number
AT99965071T
Other languages
German (de)
Inventor
Iok-Hou Pang
Original Assignee
Alcon Mfg Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Mfg Ltd filed Critical Alcon Mfg Ltd
Application granted granted Critical
Publication of ATE290866T1 publication Critical patent/ATE290866T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
AT99965071T 1998-12-03 1999-12-01 USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF NEURODEGENERATIVE OPHTHALMIC DISEASES ATE290866T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11098398P 1998-12-03 1998-12-03
PCT/US1999/028385 WO2000032197A1 (en) 1998-12-03 1999-12-01 Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases

Publications (1)

Publication Number Publication Date
ATE290866T1 true ATE290866T1 (en) 2005-04-15

Family

ID=22335984

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99965071T ATE290866T1 (en) 1998-12-03 1999-12-01 USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF NEURODEGENERATIVE OPHTHALMIC DISEASES

Country Status (16)

Country Link
EP (1) EP1135134B1 (en)
JP (1) JP2002531405A (en)
KR (1) KR100688137B1 (en)
CN (1) CN1325308A (en)
AR (1) AR022685A1 (en)
AT (1) ATE290866T1 (en)
AU (1) AU769290B2 (en)
BR (1) BR9915803A (en)
CA (1) CA2353527C (en)
DE (1) DE69924284T2 (en)
ES (1) ES2237196T3 (en)
HK (1) HK1038510B (en)
PT (1) PT1135134E (en)
TW (1) TWI246421B (en)
WO (1) WO2000032197A1 (en)
ZA (1) ZA200102714B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790344B1 (en) * 2000-07-07 2011-02-23 Spectrum Pharmaceuticals, Inc. Methods for treatment of disease-induced peripheral neuropathy and related conditions
US20020156277A1 (en) * 2001-04-20 2002-10-24 Fick David B. Synthesis and methods of use of purine analogues and derivatives
PL368565A1 (en) * 2001-08-29 2005-04-04 Alcon, Inc. Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma
EP1666068A4 (en) * 2003-09-24 2010-08-04 Santen Pharmaceutical Co Ltd Remedy for eye diseases accompanied by optic nerve injuries
CA2589001A1 (en) * 2004-11-19 2006-05-26 Kissei Pharmaceutical Co., Ltd. Preventive or therapeutic agent for neuropathic pain
EP1754474A1 (en) * 2005-02-02 2007-02-21 Eucro European Contract Research GmbH & Co. KG Use of S-Clenbuterol
EP2266559A1 (en) 2005-03-15 2010-12-29 Ono Pharmaceutical Co., Ltd. Therapeutic agent for ophthalmic disease
DK2605769T3 (en) 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
US9446015B2 (en) * 2012-10-23 2016-09-20 Nicox Science Ireland Quinone based nitric oxide donating compounds for ophthalmic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (en) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd Preventive and therapeutic agent for diabetic complication
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
AU4582797A (en) * 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
US6261545B1 (en) * 1996-09-13 2001-07-17 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
JPH10218787A (en) * 1997-02-06 1998-08-18 Akio Okamoto Ophthalmic composition based on neurotrophic factor

Also Published As

Publication number Publication date
DE69924284T2 (en) 2005-08-04
CA2353527A1 (en) 2000-06-08
BR9915803A (en) 2001-08-21
JP2002531405A (en) 2002-09-24
AU3106600A (en) 2000-06-19
CA2353527C (en) 2007-11-06
TWI246421B (en) 2006-01-01
AR022685A1 (en) 2002-09-04
AU769290B2 (en) 2004-01-22
HK1038510B (en) 2005-05-20
CN1325308A (en) 2001-12-05
ES2237196T3 (en) 2005-07-16
DE69924284D1 (en) 2005-04-21
WO2000032197A1 (en) 2000-06-08
HK1038510A1 (en) 2002-03-22
ZA200102714B (en) 2002-06-03
EP1135134B1 (en) 2005-03-16
KR20010075055A (en) 2001-08-09
EP1135134A1 (en) 2001-09-26
KR100688137B1 (en) 2007-03-09
PT1135134E (en) 2005-05-31

Similar Documents

Publication Publication Date Title
DE69936335D1 (en) USE OF MORPHOLINOL FOR THE TREATMENT OF SEXUAL FUNCTIONAL DISORDERS
DE69918687D1 (en) 4-PHENYLPIPERIDINE FOR THE TREATMENT OF PRUTITIC SKIN DISEASES
DE69724016D1 (en) USE OF ANTI-MICROTUBULI FOR TREATING INFLAMMATORY DISEASES OF THE BREATHWAYS
DE59711321D1 (en) NEW SUBSTITUTED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF HEART CIRCULAR DISEASES
ATE308997T1 (en) AGENTS FOR THE TREATMENT OF DISEASES OF THE ESOPHAUS
DE50009504D1 (en) USE OF RETIGABIN FOR THE TREATMENT OF NEUROPATHIC PAIN
DE69626539D1 (en) topical use of vitamin D for the treatment of eye diseases
DE69836752D1 (en) PROSTAGLAND INAGONIST AND ITS USE FOR THE TREATMENT OF BONE DISEASES
DE69927823D1 (en) HYDROGEL FOR THE THERAPEUTIC TREATMENT OF ANEURYSMAS
DE69941566D1 (en) N-ACETYLHOMOTAURINATES USE IN THE TREATMENT OF HYPERKINESIA
ATE292134T1 (en) NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF HEART ARHYTHMI
DE69943089D1 (en) METHOD FOR THE TREATMENT OF STAPHYLOKOCKSINFECTIONS
DE69807466D1 (en) TRIPTOLID DERIVATIVES USEFUL FOR THE TREATMENT OF AUTOIMMUNE DISEASES
ATE290866T1 (en) USE OF NEUROTROPHIC FACTOR STIMULATORS FOR THE TREATMENT OF NEURODEGENERATIVE OPHTHALMIC DISEASES
DE69729735D1 (en) USE OF BENZOPYRANOLS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
DE60018200D1 (en) USE OF PULLEOMUTILINE DERIVATIVES FOR THE TRANSDERMAL TREATMENT OF BACTERIAL DISEASES
DE69931487D1 (en) USE OF APOMORPHIN FOR THE TREATMENT OF PREMATURE EJACULATION
DE69822297D1 (en) TRIPTOLID DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DE59704933D1 (en) Use of PHMB for the treatment of tumor diseases
DE60120990D1 (en) USE OF 3-BEZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF NETWORK DISEASES
ATE230741T1 (en) 3-TETRAHYDROPYRIDINE-4-YL-INDOLE FOR THE TREATMENT OF PSYCHOTIC DISORDERS
ATE433323T1 (en) USE OF ERYTHROPOIETIN FOR THE TREATMENT OF PRIMARY HEMOCHROMATOSIS
ATE285764T1 (en) RIVASTIGMINE FOR THE TREATMENT OF EYE DISEASES
DE69918541D1 (en) USE OF NMDA ANTAGONISTS FOR THE TREATMENT COLON
DE60005685D1 (en) OXAZINOCARBAZOLE FOR THE TREATMENT OF CNS DISEASES

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135134

Country of ref document: EP